3646 results for «519»
3646 results
Innovative strategies for coronary interventions
22 May 2025 – From EuroPCR 2025
Explore innovative strategies in coronary interventions, including the EPIC26 sirolimus-eluting stent study, use of percutaneous ventricular assist devices in high-risk patients, the SCORE multicenter study on SeQuent SCB, DCB versus DES for ostial left circumflex lesions, and site-specific antithrombotic therapy outcomes from the DESyne BDS Plus...
Risk stratification of NSTEMI patients
22 May 2025 – From EuroPCR 2025
Explore the latest insights on risk stratification in NSTEMI patients through comparative analysis of established risk scores such as GRACE, HEART, and TIMI in predicting coronary artery disease severity. This session also reviews outcomes based on diabetes status and left ventricular ejection fraction, prospective validation of...
Emerging indications for TAVI in 2025
22 May 2025 – From EuroPCR 2025
Prepare for emerging TAVI indications anticipated in 2025. This session reviews clinical cases including asymptomatic severe aortic stenosis, moderate aortic stenosis with heart failure, and severe aortic regurgitation. It discusses supporting evidence from clinical trials, evolving transcatheter technologies, and practical treatment approaches for these novel indications.
Is DCB a new valid option for coronary revascularisation?
22 May 2025 – From EuroPCR 2025
This session provides an in-depth evaluation of drug-coated balloons (DCB) as a valid option for coronary revascularisation. Topics include two-year follow-up comparisons between paclitaxel and sirolimus-coated balloons, clinical outcomes after bailout stenting post-DCB angioplasty, meta-analyses contrasting DCB and DES for large native coronary artery disease, and...
Coronary sinus reducer for microvascular angina
28 Feb 2020
A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...
The 2023 ESH Hypertension Guidelines revisit the role of renal denervation
05 Sep 2023
The 2023 European Society of Hypertension (ESH) guidelines were recently presented at the 32nd annual European Meeting on Hypertension and Cardiovascular Protection and simultaneously published in the Journal of Hypertension.1 While wide parts of the guidelines do not substantially differ from the previous 2018 European Society...

Author

Author